Literature DB >> 23697317

The upper esophageal sphincter is not round: a pilot study evaluating a novel, physiology-based approach to upper esophageal sphincter dilation.

Peter C Belafsky1, Emily K Plowman, Omid Mehdizadeh, Daniel Cates, Amanda Domer, Kaicheng Yen.   

Abstract

OBJECTIVES: Recent basic science investigations have suggested that the upper esophageal sphincter (UES), in cross section, is not round, but that it more closely approximates a kidney shape. Dilation with simultaneous use of two cylindrical dilators provides a novel, physiology-based approach to UES distention. We evaluated the initial safety and efficacy of UES dilation with simultaneous use of two controlled radial expansion balloon dilators.
METHODS: Using a computerized database, we reviewed the charts of all persons who underwent UES dilation with simultaneous use of two radial expansion balloon dilators between December 1, 2011, and March 15, 2012. Information regarding patient demographics, indications, technique, and complications was abstracted. Self-reported swallowing impairment was assessed with the validated 10-item Eating Assessment Tool (EAT-10).
RESULTS: Ten individuals underwent simultaneous dilation with two dilators. Their mean age was 65 years (SD, 14 years), and 7 (70%) of them were male. The indications for dilation were radiation-induced UES stenosis (50%), cricopharyngeus muscle dysfunction (30%), upper esophageal web (10%), and anastomotic stricture (10%). After the double-balloon dilation, no complications were reported. The mean EAT-10 score improved significantly, from 34.3 (SD, 13.5) to 16.7 (SD, 8.4), after the simultaneous dilation (p = 0.003).
CONCLUSIONS: Pilot data suggest that simultaneous dilation of the UES with two controlled radial expansion balloon dilators is feasible, safe, and effective. Future investigation is necessary to confirm the safety of this technique in a larger cohort and to use objective measures of efficacy to compare the technique to conventional dilation with a single dilator.

Entities:  

Mesh:

Year:  2013        PMID: 23697317     DOI: 10.1177/000348941312200401

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  7 in total

Review 1.  Therapeutic intervention in oropharyngeal dysphagia.

Authors:  Rosemary Martino; Timothy McCulloch
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

2.  Treatment of cricopharyngeal dysfunction: a comparative pilot study.

Authors:  Beatriz Arenaz Búa; Rolf Olsson; Ulla Westin; Roland Rydell; Olle Ekberg
Journal:  BMC Res Notes       Date:  2015-07-10

3.  Treatment for upper esophageal sphincter dysfunction in a patient with poststroke dysphagia: A case report.

Authors:  Pengxu Wei; Yafei Xu; Zuting Zhang; Simin Zhang; Zeping Lv
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

4.  Effectiveness of Rehabilitative Balloon Swallowing Treatment on Upper Esophageal Sphincter Relaxation and Pharyngeal Motility for Neurogenic Dysphagia.

Authors:  Yong Kyun Kim; Sung Sik Choi; Jung Hwa Choi; Jeong-Gyu Yoon
Journal:  Ann Rehabil Med       Date:  2015-08-25

5.  Improved symptomatic, functional, and fluoroscopic outcomes following serial "series of three" double-balloon dilation for cricopharyngeus muscle dysfunction.

Authors:  Derrick R Randall; Lisa M Evangelista; Maggie A Kuhn; Peter C Belafsky
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-05-15

6.  Three-dimensional imaging of upper esophageal sphincter resting pressure.

Authors:  Shun-Ichi Chitose; Yasuro Shin; Kiminori Sato; Sachiyo Hamakawa; Mioko Fukahori; Takeharu Ono; Hirohito Umeno
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-11-11

7.  Simultaneous double balloon dilatation using double channel therapeutic endoscope in patients with cricopharyngeal muscle dysfunction: An observative study.

Authors:  Yong Seob Jo; Jung Hyun Cha; Yong Kyun Kim; Sun Young Kim; Hong Sub Lee
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.